- Home
- SNN vs UTHR Comparison
SNN vs UTHR Comparison
Compare SNN & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNN
- UTHR
- Stock Information
- Founded
- SNN 1856
- UTHR 1996
- Country
- SNN United Kingdom
- UTHR United States
- Employees
- SNN N/A
- UTHR N/A
- Industry
- SNN Industrial Specialties
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- SNN Health Care
- UTHR Health Care
- Exchange
- SNN Nasdaq
- UTHR Nasdaq
- Market Cap
- SNN 12.7B
- UTHR 14.4B
- IPO Year
- SNN 1999
- UTHR 1999
- Fundamental
- Price
- SNN $28.96
- UTHR $321.62
- Analyst Decision
- SNN Hold
- UTHR Buy
- Analyst Count
- SNN 3
- UTHR 12
- Target Price
- SNN $27.50
- UTHR $392.00
- AVG Volume (30 Days)
- SNN 584.4K
- UTHR 477.3K
- Earning Date
- SNN 02-25-2025
- UTHR 04-30-2025
- Dividend Yield
- SNN 2.59%
- UTHR N/A
- EPS Growth
- SNN 56.15
- UTHR 18.86
- EPS
- SNN 0.47
- UTHR 25.10
- Revenue
- SNN $5,810,000,000.00
- UTHR $2,994,100,000.00
- Revenue This Year
- SNN $6.87
- UTHR $14.37
- Revenue Next Year
- SNN $5.19
- UTHR $6.05
- P/E Ratio
- SNN $30.75
- UTHR $12.70
- Revenue Growth
- SNN 4.70
- UTHR 19.84
- 52 Week Low
- SNN $23.69
- UTHR $266.98
- 52 Week High
- SNN $31.72
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- SNN 58.60
- UTHR 64.44
- Support Level
- SNN $28.55
- UTHR $311.62
- Resistance Level
- SNN $29.21
- UTHR $320.91
- Average True Range (ATR)
- SNN 0.37
- UTHR 7.17
- MACD
- SNN -0.02
- UTHR 1.63
- Stochastic Oscillator
- SNN 64.71
- UTHR 89.55
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.